NEW YORK, NY, Jan. 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as an ongoing Pharmaceutical Development initiative, today announced that it is constructing a Product Showroom (“Showroom”) inside its new corporate headquarters.  The Company has made this decision in anticipation of and in preparation for important future Agreement(s) & Partnership(s).  The Company expects to host a broad array of prospective new customers, once this Showroom is functional.  These potential new customers include, but are not limited to: Individual Customers, Mom & Pop Stores, Gas Station Convenience Stores, Large Regional & National Retailers, Major Distributors, and College Campus Stores.

Read this article:
Tauriga Sciences Inc. to Construct Product Showroom Within its New Corporate Headquarters

Global News Feed Comments Off on Tauriga Sciences Inc. to Construct Product Showroom Within its New Corporate Headquarters | January 19th, 2021

President and CEO Sanjeev Luther and Co-Chief Medical Officer Tim Pardee, M.D., Ph.D., will discuss clinical trial launches, FDA-granted Fast Track designations and other recent accomplishments on Wednesday, Jan. 20 President and CEO Sanjeev Luther and Co-Chief Medical Officer Tim Pardee, M.D., Ph.D., will discuss clinical trial launches, FDA-granted Fast Track designations and other recent accomplishments on Wednesday, Jan. 20

Visit link:
Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference

Global News Feed Comments Off on Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference | January 19th, 2021

1 Growth at constant exchange rates and scope is the organic growth of sales, excluding the impact of exchange rate changes, by calculating the indicator for the financial year in question and that for the previous financial year on the basis of identical exchange rates (the exchange rate used is that in effect for the previous financial year), and excluding the impact of changes in scope, by calculating the indicator for the financial year in question on the basis of the scope of consolidation for the previous financial year, and by excluding sales of Sentinel for the two financial years in question.

View original post here:
VIRBAC:2020 annual revenue shows strong growth of +5.7% at constant exchange rates and scope (+3.2% at constant rates)

Global News Feed Comments Off on VIRBAC:2020 annual revenue shows strong growth of +5.7% at constant exchange rates and scope (+3.2% at constant rates) | January 19th, 2021

LEXINGTON, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, and Dr. Steven O’Day, CMO of Agenus, will participate in B. Riley Securities’ Oncology Investor Conference on January 20-21, 2021.

More here:
Agenus to Participate in B. Riley Securities' Oncology Investor Conference

Global News Feed Comments Off on Agenus to Participate in B. Riley Securities’ Oncology Investor Conference | January 19th, 2021

18 January 2021

A new way of controlling the immune system's 'natural killer' cells has been identified, which could help prevent rejection of transplanted cells.

Natural killer cells act as a front-line defence against foreign cells in the body. Overcoming this defence has represented a major challenge to transplant, cancer immunotherapy and regenerative medicine. The new research provides a possibility to disguise transplanted cells so that they are 'invisible' to this immune defence.

'As a cardiac surgeon, I would love to put myself out of business by being able to implant healthy cardiac cells to repair heart disease', said the study's lead author Professor Tobias Deuse, from the Department of Surgery at University of California, San Francisco. 'And there are tremendous hopes to one day have the ability to implant insulin-producing cells in patients with diabetes or to inject cancer patients with immune cells engineered to seek and destroy tumours. The major obstacle is how to do this in a way that avoids immediate rejection by the immune system'.

Professor Deuse and his colleagues genetically engineered cells to express the protein CD47 and found that these were not attacked by natural killer cells. They discovered that this was because the CD47 protein activates another protein found in the natural killer cells called SIRP.

SIRP was known to be important in other immune cell responses, but scientists had not previously been able to identify it in natural killer cells. 'All the literature said that natural killer cells don't have this checkpoint, but when we looked at cells from human patients in the lab we found SIRP there, clear as day', said corresponding author Professor Sonja Schrepfer.

The team investigated whether this finding could be used to help transplanted stem cells to avoid immune rejection. To do this, they genetically engineered human cells to express rhesus monkey CD47 and transplanted these cells into monkeys. They found that the engineered cells activated the SIRP on natural killer cells, which prevented them from being attacked.

In the future the same procedure could be performed in reverse, expressing human CD47 in pig cardiac cells, for instance, to prevent them from activating natural killer cells when transplanted into human patients.

The research team aims to create a 'hypoimmune' cell line for use in regenerative medicine that will be able to avoid immune rejection.

'Currently engineered cell therapies for cancer and fledgling forms of regenerative medicine all rely on being able to extract cells from the patient, modify them in the lab, and then put them back in the patient. This avoids rejection of foreign cells, but is extremely laborious and expensive', said Professor Schrepfer. 'Our goal in establishing a hypoimmune cell platform is to create off-the shelf products that can be used to treat disease in all patients everywhere'.

The research was recently published in the Journal of Experimental Medicine.

Read more:
Controlling the immune system with 'invisible stem' cells - BioNews

Cardiac Stem Cells Comments Off on Controlling the immune system with ‘invisible stem’ cells – BioNews | January 19th, 2021

PFFFIKON, Switzerland, Jan. 19, 2021 /PRNewswire/ -- DiNAQOR, a gene therapy platform company,today announcedthat it has acquired EHT Technologies GmbH, a Germany-based engineered heart tissue (EHT) technology platform company. Financial terms of the transaction were not disclosed.

EHT Technologies was founded in 2015 based upon research on human induced pluripotent stem cells (hiPSC) at the University Medical Center Hamburg-Eppendorf. Cardiomyocytes derived from hiPSC are an innovative research technology for cardiac drug development programs. Engineered heart tissues are three-dimensional, hydrogel-based muscle constructs that can be generated from isolated heart cells of chicken, rat, mouse, human embryonic stem cells and hiPSC. Proof-of-concept studies have shown that EHT can be transduced efficiently with adeno-associated virus (AAV) vectors, including AAV9, validating the use of this platform for gene therapy applications.

"EHT Technologies' proprietary hiPSC platform for disease modeling is a perfect complement to DiNAQOR's research and development efforts and leaps forward our ability to develop creative approaches for treating heart diseases in the future. EHT's intellectual property and know-how is industry-leading and we are excited to be able to harness its platform at DiNAQOR," commented Johannes Holzmeister, M.D., Chairman and CEO at DiNAQOR.

"After more than 25 years of development, I'm very excited that our engineered heart tissue technology is making the transition from an academic research model to a drug development tool. The combined application of human cardiomyocytes and a versatile, 3D in vitro assay will facilitate development and reduce reliance on animal studies. The hiPSC-derived EHT assay has great potential for the development of innovative cardiovascular therapeutics and DiNAQOR is the perfect fit for this enterprise," commented Professor Thomas Eschenhagen, M.D., co-founder of EHT Technologies. Professor Eschenhagen serves on DiNAQOR's Scientific Advisory Board.

"The EHT technology will accelerate the advancement of our discovery pipeline and bridge the translational gap between the animal model and human disease. We are proud that DiNAQOR is on the forefront of implementing this innovative technology to expedite new therapies into the clinic," said Valeria Ricotti, M.D., Chief Medical Officer at DiNAQOR.

About DiNAQORFounded in 2019,DiNAQOR is a global gene therapy platform company focused on advancing novel solutions for patients suffering from heart disease.The company is headquartered in Pfffikon, Switzerland, with additional presence in London, England and Hamburg, Germany. For more information visitwww.dinaqor.com.

ContactKWM CommunicationsKellie Walsh[emailprotected] or Stephanie Marks[emailprotected]

SOURCE DiNAQOR

DiNAQOR: A global gene therapy platform company

See the article here:
DiNAQOR Acquires EHT Technologies GmbH to Advance Engineered Heart Tissue R&D Capabilities - PRNewswire

Cardiac Stem Cells Comments Off on DiNAQOR Acquires EHT Technologies GmbH to Advance Engineered Heart Tissue R&D Capabilities – PRNewswire | January 19th, 2021

Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis

Company Announcement

Copenhagen, Denmark; January 15, 2021 Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (U.S. FDA) has approved the use of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide, and dexamethasone (VCd) for the treatment of adult patients with newly diagnosed light-chain (AL) amyloidosis. A supplemental Biologics License Application (sBLA) for this indication was submitted by Janssen Biotech, Inc. (Janssen), in September 2020. The U.S. FDA reviewed the submission of data for approval in this indication under their Real-Time Oncology Review (RTOR)1 pilot program and Project Orbis2. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). DARZALEX FASPRO is not indicated and is not recommended for the treatment of patients with light-chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials. In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize daratumumab.

AL amyloidosis is a devastating and potentially fatal blood disorder that, until now, did not have any U.S. FDA-approved therapies. This makes todays approval of DARZALEX FASPRO a critical step forward for patients in the U.S. in dire need of treatment options, said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

The approval was based on data from the Phase 3 ANDROMEDA (AMY3001) study of daratumumab and hyaluronidase-fihj in combination with VCd as treatment for patients with newly diagnosed AL amyloidosis.

The most common adverse reactions (20%) were upper respiratory tract infection, diarrhea, peripheral edema, constipation, fatigue, peripheral sensory neuropathy, nausea, insomnia, dyspnea and cough. Serious adverse reactions occurred in 43% of patients who received DARZALEX FASPRO in combination with VCd. Serious adverse reactions that occurred in at least 5% of patients in the D-VCd arm were pneumonia (9%), cardiac failure (8%) and sepsis (5%). Fatal adverse reactions occurred in 11% of patients. Fatal adverse reactions that occurred in more than one patient included cardiac arrest (4%), sudden death (3%), cardiac failure (3%) and sepsis (1%).3

Among patients who received DARZALEX FASPRO in combination with VCd, 72% of patients had baseline cardiac involvement with Mayo Cardiac Stage I (3%), Stage II (46%) and Stage III (51%). Serious cardiac disorders occurred in 16% of patients (8% of patients with Mayo Cardiac Stage I and II and 28% of patients with Stage III). Serious cardiac disorders in more than 2% of patients included cardiac failure (8%), cardiac arrest (4%) and arrhythmia (4%). Fatal cardiac disorders occurred in 10% of patients (5% of patients with Mayo Cardiac Stage I and II and 19% of patients with Stage III) who received DARZALEX FASPRO in combination with VCd. Fatal cardiac disorders that occurred in more than one patient in the D-VCd arm included cardiac arrest (4%), sudden death (3%) and cardiac failure (3%).3

Full prescribing information will be available at http://www.DARZALEX.com.

Genmab will receive a milestone payment of USD 30 million in connection with the first commercial sale of DARZALEX FASPRO in this indication, which is expected to occur quickly after approval. The milestone will be reflected in Genmabs 2021 guidance, which will be published on February 23, 2021.

About the ANDROMEDA (AMY3001) studyThe Phase 3 study (NCT03201965) included 388 patients newly diagnosed with AL amyloidosis. Patients were randomized to receive treatment with either daratumumab and hyaluronidase-fihj in combination with bortezomib (a proteasome inhibitor), cyclophosphamide (a chemotherapy), and dexamethasone (a corticosteroid) or treatment with VCd alone. The primary endpoint of the study was the percentage of patients who achieve hematologic complete response.

About Light-chain (AL) AmyloidosisAmyloidosis is a disease that occurs when amyloid proteins, which are abnormal proteins, accumulate in tissues and organs. When the amyloid proteins cluster together, they form deposits that damage the tissues and organs. AL amyloidosis most frequently affects the heart, kidneys, liver, nervous system and digestive tract. Until now there were no approved therapies for AL amyloidosis in the U.S., though it is currently being treated with chemotherapy, dexamethasone, stem cell transplants and supportive therapies.4 It is estimated that there are approximately 3,000 to 4,000 new cases of AL amyloidosis diagnosed annually in the U.S.5

About DARZALEX (daratumumab)DARZALEX (daratumumab) has become a backbone therapy in the treatment of multiple myeloma. DARZALEX intravenous infusion is indicated for the treatment of adult patients in the United States: in combination with carfilzomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma who have received one to three previous lines of therapy; in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI); and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.6 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (U.S. FDA) approval to treat multiple myeloma.

DARZALEX is indicated for the treatment of adult patients in Europe via intravenous infusion or subcutaneous administration: in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; and as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy7. Daratumumab is the first subcutaneous CD38 antibody approved in Europe for the treatment of multiple myeloma. The option to split the first infusion of DARZALEX over two consecutive days has been approved in both Europe and the U.S.

In Japan, DARZALEX intravenous infusion is approved for the treatment of adult patients: in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for the treatment of relapsed or refractory multiple myeloma. DARZALEX is the first human CD38 monoclonal antibody to reach the market in the United States, Europe and Japan. For more information, visit http://www.DARZALEX.com.

DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, is approved in the United States for the treatment of adult patients with newly diagnosed light-chain (AL) amyloidosis in combination with bortezomib, cyclophosphamide, and dexamethasone. It is also approved in the U.S. for the treatment of adult patients with multiple myeloma: in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for ASCT; in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for ASCT and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy; in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and as monotherapy, in patients who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.8 DARZALEX FASPRO is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE drug delivery technology. .DARZALEX FASPRO is the first subcutaneous CD38 antibody approved in the U.S. for the treatment of multiple myeloma and the first and only approved treatment for patients with AL amyloidosis in the U.S.

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. Daratumumab triggers a persons own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).6,9,10,11,12

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A comprehensive clinical development program for daratumumab is ongoing, including multiple Phase III studies in smoldering, relapsed and refractory and frontline multiple myeloma settings. Additional studies are ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases in which CD38 is expressed, such as amyloidosis and T-cell acute lymphocytic leukemia (ALL). Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA for certain indications of multiple myeloma, including as a monotherapy for heavily pretreated multiple myeloma and in combination with certain other therapies for second-line treatment of multiple myeloma.

About Genmab Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmabs proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com.

Contact: Marisol Peron, Corporate Vice President, Communications & Investor Relations T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations: Andrew Carlsen, Senior Director, Investor RelationsT: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmabs most recent financial reports, which are available on http://www.genmab.com and the risk factors included in Genmabs most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at http://www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab; the Y-shaped Genmab logo; Genmab in combination with the Y-shaped Genmab logo; HuMax; DuoBody; DuoBody in combination with the DuoBody logo; HexaBody; HexaBody in combination with the HexaBody logo; DuoHexaBody; HexElect; and UniBody. DARZALEX and DARZALEX FASPRO are trademarks of Janssen Pharmaceutica NV.

1 Real-Time Oncology Review Pilot Program. https://www.fda.gov/about-fda/oncology-center-excellence/real-time-oncology-review-pilot-program Accessed September 20202 Project Orbis. U.S. Food and Drug Administration. https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis. Accessed September 2020.3DARZALEX FASPRO Prescribing Information. Horsham, PA: Janssen Biotech, Inc.4 Mayo Clinic website: http://www.mayoclinic.com/health/amyloidosis/DS004315 Research and Markets, Amyloidosis Treatment Market Size, Share & Trends Analysis Report by Treatment (Stem Cell Transplant, Chemotherapy, Supportive Care, Surgery, Targeted Therapy), By Country, And Segment Forecasts, 2018 - 20256 DARZALEX Prescribing information, August 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761036s029lbl.pdf Last accessed August 20207 DARZALEX Summary of Product Characteristics, available at https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex Last accessed June 20208 DARZALEX FASPRO Prescribing information, May 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761145s000lbl.pdf Last accessed May 20209 De Weers, M et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848.10 Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-21.11 Krejcik, MD et al. Daratumumab Depletes CD38+ Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma. Blood. 2016; 128: 384-94.12 Jansen, JH et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking. Blood. 2012; 120(21): abstract 2974

Read more:
Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for Patients with Newly Dia...

Cardiac Stem Cells Comments Off on Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for Patients with Newly Dia… | January 19th, 2021

As the air continues to dry and temperatures drop, the yearly battle against dry hands and skin has officially begun. New research from Northwestern University has discovered new evidence deep within the skin about the mechanisms controlling skin renewal and repair.

Skins barrier function gives it the unique ability to fight winter woes and keep water for our bodies. The outer layer of the skin, the skin, is constantly turning over to replace damaged or dead cells, creating new cells to reinforce the barrier function and heal damage. The gene regulatory mechanisms that control epidermis turnover remain incompletely understood.

Every month were covered with a new layer of the epidermis, said Northwesterns Xiaomin Bao, who headed the study. The next question is what does that procedure involve?

The newspaper will be published on Jan. 19 in the journal Nature Communications.

GeneticjunkThe scientific community has developed a wide breadth of knowledge about proteins, the workhorses of various cellular activities. Many mysteries remain about the nature of introns, non-coding segments of DNA that make up 24% of the human genome.

Regardless of the general belief that introns are nothing butgenetic junk, they actually play critical roles in modulating RNA transcription throughout a tissues lifespan. RNA transcription is the first step of gene expression, in which the data from DNA is copied into RNA, which is then subsequently used as a template for synthesizing proteins to drive the specific function of a cell.

Based on where transcription terminates within an intron or at the conclusion of a gene an epidermal stem cell will either remain a stem cell or become a specified cell barrier function. Bao said while its well-known that transcription ends at the end of a gene, her labs research found conflicting data.

Future research could have implications for carcinoma research.

Technology critical to the discovery of the phenomenonSkin cells are gaining popularity with researchers in part because of their regenerative properties and readiness to grow in cultures. This allows researchers to apply an assortment of state-of-the-art technologies. By growing skin cells and regenerating skin tissue in a petri dish, the Bao Lab can experiment with this fast-growing tissue to determine molecular mechanisms and regulatory elements within DNA.

Technology development is an integral driver that enabled us to uncover this new phenomenon, Bao said.

The group used a novel genomic technique that maps where transcription stops. The integration of proteomic approaches identified RNA-binding proteins which read specific regulatory sequences in the introns.

The team further leveraged CRISPR technologies to delete genomic sequences in the intron, which provided direct evidence demonstrating that the crucial roles of introns in modulating gene expression.

Before this study, mechanisms between introns to govern the switch between a skin stem cell and a terminally differential state (for example, a cell that participates in forming a skin barrier), were unknown. Most studies ignored introns, despite them accounting for 10 to 20 times more sequences than the protein-coding regions (exons) in the human genome.

The study demonstrates that different genes may involve different sets of RNA-binding proteins to recognize the regulatory sequences in their introns. These RNA-binding proteins help to mature RNAdecide whether to cut transcription early or dismiss termination sites within an intron during differentiation due to changes in protein availability.

We are only starting to appreciate the roles of the intron in human health and diseases, Bao said.

Results of this study could have broader impacts because, according to Bao, the procedures regulating skin cells are almost definitely not restricted to skin cells. Future research on other systems, including other epithelial tissues, will likely uncover similar patterns.

We are extremely hopeful that what weve found is the first step to knowing what we have ignored in the past, Bao said. My students also wish to know more about the RNA binding proteins which provide specificity in governing which site to use to terminate transcription.

Source:

View post:
Research finds new proof about the systems controlling skin repair and regeneration - Microbioz India

Skin Stem Cells Comments Off on Research finds new proof about the systems controlling skin repair and regeneration – Microbioz India | January 19th, 2021

This article was originally published here

Hum Gene Ther. 2021 Jan 15. doi: 10.1089/hum.2020.275. Online ahead of print.

ABSTRACT

Wound healing has been greatly challenging in different acute and chronic skin injuries. Among them, non-revascularizable critical limb ischemic ulcers, venous leg ulcers, and diabetic lower limb or extremity ulcers are well-known refractory skin injuries that are difficult to treat. Partly differentiated progenitor cell-based graft transplantation or direct injection of autologous stem cells might promote the wound healing process. Studies aiming to comprehensively analyze the effects of cell therapy on skin wound healing could provide clinical evidence for skin injury treatment. Different databases were searched for full-text publications about the comparison between cell therapy and regular therapy. Heterogeneity was detected by the I2 method, and a fixed-effect model was applied for data pooling if heterogeneity was absent. Publication bias was analyzed using a funnel plot, and 10 studies were finally included in this study. After a long-term follow-up, fewer patients underwent major amputation in the cell therapy group, compared with the standard therapy group, and those in the cell therapy group were characterized with smaller ulcer area. Moreover, there was a significant difference in the wound healing rate between the intervention and control groups. However, pain caused by skin wounds was hardly mitigated by cell therapy in patients with critical limb ischemia. In this study, cell therapy proved effective in decreasing the size of ulcer and improving wound closure rate. Additionally, major amputation rate was decreased in the cell therapy group. However, the symptoms of pain were hardly alleviated by cell therapy in patients with cutaneous ulcers caused by peripheral artery disease-related critical limb ischemia.

PMID:33446038 | DOI:10.1089/hum.2020.275

View post:
Comprehensive analysis of cell therapy on chronic skin wound healing: a meta-analysis - DocWire News

Skin Stem Cells Comments Off on Comprehensive analysis of cell therapy on chronic skin wound healing: a meta-analysis – DocWire News | January 19th, 2021

Most of us would agree that 2020 was the shortest long year, one in which you probably lost track of your routines. Although 2021 might be off to a rocky start because of political unrest and ongoing COVID-19 shutdowns, its as good a time as any to take inventory of how you can improve your daily rituals.

Studies have shown that there is a psychological benefit to self-care. Grooming is important for human behavior because it makes us feel better and it boosts our self-esteem, said Dr. Amy Wechsler, a New York-based psychiatrist and dermatologist. When people are stressed, they stop doing their routines. Routines are important. They give us a sense of control, and right now people feel really out of control. Little ways to give you back the feeling or semblance of control are helpful.

For starters, Wechsler recommends maintaining your skincare regimen. A few minutes in the morning, she said. A few minutes in the evening. It helps ground a lot of people.

Here are tips and tricks from beauty and wellness experts:

Cassandra Grey, founder of L.A. beauty boutique Violet Grey, says that skincare as a category has been on the rise over the last four years. 70% of her business sales come from skincare while 25% of her customers are men.

(Naj Jamai)

Cassandra Grey, founder of Los Angeles beauty boutique Violet Grey, has built her business around a belief in grooming and wellness as an important form of self-care. Humans are motivated by three things sex, power and self-respect, she said. I think skincare or self-care or beauty products that enhance the way you feel or the way that you look really help you achieve self-respect because you feel like youre taking care of yourself.

One of Violet Greys bestsellers is Augustinus Baders the Cream, which has become something of a phenomenon since the German brand launched three years ago. It just works, Grey said of the cream (15 milliliters, $85), which reportedly triggers existing stem cells to repair skin. You use it, and your skin looks better. Period. Thats why its become a hero product. It is innovative in the formulation. There is not a formulation like that.

One of Violet Greys bestsellers is Augustinus Baders the Cream. Three new Augustinus Bader products a cleansing gel, body lotion and body oil were added to the brands lineup.

(Augustinus Bader)

The skincare brand, which was created by leading stem cell and biomedical scientist Augustinus Bader, has released a cleansing gel (100 milliliters, $65), body lotion (30 milliliters, $35; 100 milliliters, $95) and body oil (100 milliliters, $95), which all contain the companys proprietary technology, a combination of natural amino acids, high-grade vitamins and synthesized molecules.

There are a number of result-driven brands and products on the market.

Among them are Protocol, which packages its Complete Renewing Line (four skincare products for $262) in airless, UV-proof bottles in order to protect its products oxidized retinol and L-ascorbic acid ingredients; L.A.-based Youth to the Peoples pro-grade vegan Protect the Planet Refillable Minis Kit ($60); Goops Glowing Skin Bestsellers Kit ($79), which includes the Santa Monica-based skincare companys top three products (an exfoliator, face peel and super-powder); New Zealand-based clean beauty brand Emma Lewisham whose Skin Shield Daily Face Antioxidant Protect + Repair SPF 30 ($57) is packaged in 100% post-consumer-recycled container; the Beauty Chefs Glow Inner Beauty Essential, a powder-based vitamin whole-food supplement ($65); and Chanels La Solution 10 De Chanel moisturizer (1 ounce, $80), the latter of which Wechsler helped formulate as the luxury brands consulting dermatologist.

Beyond skincare and cosmetics, Grey said her company has seen a rise in wellness products during the last year. Weve sold a lot of vibrators, a lot of candles, she said, recommending Craves Vesper Vibrator ($69) and Heretics Dirty Grass Candle ($85). Its these rituals where youre taking care of yourself and youre getting present and in the moment and youre feeling some comfort.

However, carving out time for oneself, especially during the ongoing pandemic, can be quite a challenge, Grey said. I wish I could say I was better at practicing what I preach, she said, but I think its always been a struggle for me to find balance between work, myself, my family and particularly now with us all sleeping at our offices. Were not working from home anymore. Its like were sleeping at our office.

DRX Spectralite Faceware Pro by Dr. Dennis Gross, $435.

(Dr. Dennis Gross)

With limited time in our schedules for ourselves, Grey advises combining self-care tasks. I do a treatment while I meditate because a lot of these treatments take time, she said, adding that a few of her favorites include Dr. Dennis Gross DRX Spectralite Faceware Pro ($435), Hanacures all-in-one-facial starter kit ($29) and Leonor Greyls scalp treatment ($48).

You feel refreshed, Grey said of meditating, mentioning that she favors YouTubes various free meditation videos. I think a lot of people dont meditate because they feel like they dont know how to do it, or they try to sit still and they just cant because they have so many thoughts or distractions or whatever. Its just about sitting still. Even if you dont get into a deep unconscious meditative hypnosis, its still healthy to sit still and try to get even just a moment of being present.

Iris & Romeos 3-in-1 Power Peptide Lip Balm ($26) is available at irisandromeo.com.

(Iris & Romeo)

Keeping up a routine through this stay-at-home period is really vital, but its about connecting with yourself, said Michele Gough Baril, founder of Northern California-based beauty brand Iris & Romeo. Thats when youll feel calmer, grounded and connected. Having a modified beauty routine that makes you feel good, makes you feel connected but doesnt feel like a chore is critical. Its also important to get ready for yourself, not for others.

Gough Baril launched her brand in 2019 after a personal lesson in self-care. In 2012, she was head of marketing for Smashbox, but after she helped grow the former indie company into a global Estee Lauder-acquired brand, Gough Baril decided to step away from the beauty industry. I was completely burnt out, she said. I think this is really a common thing for a lot of women. We give so much, and we never take care of ourselves. And everything else comes first. Theres the needs of the family, the needs of the business, the needs of everything. It was really a time in my life where I hit that wall.

After a year of soul searching, Gough Barils created Iris & Romeo, which, she said, stands for all the things that I believe in sustainability, clean beauty; a brand that supports the burned-out modern woman and her mental, spiritual and emotional health.

Gough Baril launched just two skincare/makeup hybrid products in varying shades after exploring what makes [people] feel good. For me, its hydrated dewy skin and lips, she said. The brands Best Skin Days ($64) combines five products into one; its a serum, moisturizer and SPF that provides coverage and blue light/pollution protection. Women want a simplified routine, she said. What is the least you need to do to make you feel like the best version of yourself?

Chanels Rouge Allure Velvet Extreme matte lip color in Pivoine Noire ($40), left, and Rogue Allure Laque Ultrawwear shine liquid lip color ($40) are from the brands new Les Fleurs de Chanel spring/summer 2021 collection available at chanel.com.

(Chanel)

Gabrielle Coco Chanel used to say, If youre sad, add more lipstick and attack, hence the brands wide array of Rouge Allure ($40) lipsticks. However, Gough Baril said theres a time and place for a red lip versus her brands 3-in-1 Power Peptide Lip Balm ($26). For Chanel, it was about the power lip, she explained. That bold red lip has a psychological effect. I wear one when I go on VC meetings. Theres something about putting on a bold red lip that makes me feel like Im in charge. But for me, the modern woman, what shes going to use every day is a lip balm, a little hint of color.

Gough Baril acknowledged theres no need for lipstick beneath a COVID-19-era face mask but said Iris & Romeos lip balms add the perfect pop of color for video-conference meetings. You just need enough to make you feel polished and pulled together, she said. Even though youre wearing your sweatpants on the bottom; on the top, you want to have a little bit of [something]. It affects your mindset. It helps you pull yourself together and say, Im ready to face the day.

Although quarantine might seem like a good time to try new products, Wechsler warned that its important to listen to your skin as you experiment. If youre buying new product, test it out under a small area on your face for three nights or three days to make sure it doesnt bug you, she said. Dont make huge, drastic changes. If you have a reaction and you used five new things, then you dont know what its from. Just add one thing at a time if youre changing, and be weary of a lot of strong fragrance in some things. A lot of plant extracts are irritating. Just go slowly. One new thing at a time.

Also, buyer beware: adult acne has seen a rise during the pandemic. Some professionals have been quick to label it mask-ne, but Wechsler has a different theory. Stress is known to cause acne, she said. I do think certain [rougher] mask materials can irritate patients skin, and certain mask materials make people sweat more and may make them break out more. But I think its the stress more than it is the mask.

To combat the problem, she advised that people look at their sleep patterns or, as she called it, sleep hygiene. According to Wechsler, adults need 7 to 8 hours of sleep a night. We heal in our sleep, said the author of The Mind-Beauty Connection.

Wechsler suggests monitoring your bedtime habits. Theres no way you can turn off [the] news and fall asleep in 10 minutes, she said, recommending you take a break from technology two hours before heading to bed. Play a game. Read a novel. Watch a comedy. Have sex, she said, explaining that a stress-induced bad night of sleep can lead to a poor complexion.

She also recommended double checking your products. A patient will come in and say, I have not changed any of my skincare products but now Im getting this rash, she said, explaining that its often the result of noncomedogenic products. A comedo is a blackhead or a whitehead. [Noncomedogenic] essentially means it wont clog your pores and cause pimples.

Her top advice: make sure you wash your face when you come home from being outside and wash your mask after each use. Ive found a lot of people not doing that, she said.

Acne can also be treated with salicylic acid, which, Wechsler said, is a nice over-the-counter ingredient. Conversely, she doesnt recommend products with benzoyl peroxide. Its really irritating, she said.

Consider your alcohol intake to keep your skin looking fresh. A list of products from brands making sustainable wine and drink alternatives and additives includes Rescue Ros, left, Kin Euphorics Kin Spritz drink, Brighter sparkling drink and Renudes Chagaccino coffee boost.

(Rescue Ros; Kin Euphorics; Brighter; Renude)

Another consideration is alcohol intake. If you drink too much, your skin will be dehydrated, Wechsler said, adding that its not known if one type of beverage is better than another. Its theorized, but that study has not been done. She said that peoples cocktail preferences and its effects are individualized but that generally speaking, drinking too much can harm how one sleeps.

If you need a drink, opt for biodynamic, organic and sustainable wines. After all, wine is known to have healthy antioxidants in it, Wechsler said.

Our suggestions: Rescue Ros, a sustainable California ros wine from Los Angeles-based stylist and animal lover Nola Singer. The wine retails for $25 at rescuerose.com and benefits Los Angeles Love Leo Rescue, a nonprofit that aids animals in need.

Or consider swapping alcohol for a healthier beverage. Kin Euphorics Kin Spritz is a nonalcoholic spirit,made of adaptogens, nootropics and botanics, which includes a blend of fresh citrus, warm spice, hibiscus and ginger. A four pack is $27 at kineuphorics.com.

Another option is Santa Monica-based Brighter, a sparkling tonic with prebiotics, acetic acid and apple cider vinegar, which might be refreshing but also supports gut health. Sold in a 12-pack for $34.99 at brightertonic.com, Brighters flavors include lemon ginger turmeric and mlange.

Lastly, Chagaccino is a new mushroom and adaptogenic coffee additive from West Hollywood-based Renude that reportedly helps relieve stress, boost immunity and has anti-aging benefits because of its clean, plant-based, antioxidant-filled ingredients. Each box includes 10 packets for $29.99 at drinkrenude.com.

Hairstylist Ted Gibson says self-care begins by taming ones tresses. Hair can transform not only the way that you look but also the way that you feel, he says.

(Ted Gibson)

Celebrity hairstylist Ted Gibson said that for many women self-care begins with taming ones hair. Hair can transform not only the way that you look but also the way that you feel, he said, noting that many of the women who have come to Starring by TedGibson, his Los Angeles-based hair salon, were eager to make major changes to their hair during the salons pandemic reopening.

They felt like before COVID they were one woman and after COVID are another, he said, adding that theres a psychological connection between hair and ones mood. It does make you feel better when you walk past a mirror and your hair is done [even if] youre in a pair of sweats.

His clients often associate their hair with major milestones in their personal lives, he said. If you ask a woman of a certain age, What defines you?, shell definitely refer to different hairstyles, he said, and different periods of her life.

From top to bottom and left to right: Headbands and hair accessories from Lelet NY ($168), LeLe Sadoughi X Stoney Clover Lane ($195), Ulla Johnson ($65), Sarah J. Curtis ($17), Tarina Tarantino ($55) and Suryo ($71).

(Lelet NY; LeLe Sadoughi X Stoney Clover Lane; Ulla Johnson; Sarah J. Curtis; Tarina Tarantino; Suryo)

Gibson said this pandemic is no different, and there are a number of quick at-home tricks to add a bit of style without much effort. One easy option is to change your hairs part. If youre always used to having your hair down the center, change your part to the side, Gibson said. It gives a whole new kind of sophistication because a center part can be a little girl-next-door and then a side part could be just a little sexier.

Another fix? A hair accessory can always go a long way, Gibson said, adding that a headband or jeweled barrette can make a nice addition to a ponytail or messy top knot to add a little oomph to your next video call, romantic date night in the backyard or mirror selfie.

A number of fashion and accessory labels have options including LeLe Sadoughi X Stoney Clover Lane, Sarah J. Curtis, Lelet NY, Suryo, Ulla Johnson and Tarina Tarantino.

When it comes to daily hair maintenance, Gibson said that most of his clients say theyve been shampooing every other day, which he supports; however, he said that hair does need a daily styling refresher.

Starring by Ted Gibsons Shooting Star Texture Meringue, $52.

(Ted Gibson)

Whether your hair is curly or straight or you want it to be a voluminous blow dry or after you put in some really beautiful beachy waves and you want the hair to have a tasseled feel to it, Starring Shooting Star Texture Meringue is the product I go to, he said of the $52 weightless mousse he created to use as a universal styling tool. I needed something that I could pull out of my bag that I could use on Debra Messing, Gabrielle Union, Lupita Nyongo and Sandra Oh. He said he uses it on himself as well because of its provocative fig, coconut and amber scent.

For her part, Gough Baril is quick to point out that hair, skincare and beauty routines merely scratch the surface when it comes to daily wellness practices.

The emotional, the physical and the spiritual well-being of a woman is interconnected, she said. Self-care is not just a pedicure.

Link:
COVID self-care tips for skin, hair and overall wellness - Los Angeles Times

Skin Stem Cells Comments Off on COVID self-care tips for skin, hair and overall wellness – Los Angeles Times | January 19th, 2021

Tess Daly has admitted she is now "less obsessed" with how she looks since hitting her 50th birthday and is grateful to her body for giving her healthy children and a long career.

The Strictly Come Dancing presenter and mum-of-two, now 51, says she regularly sees signs of ageing like wrinkles and grey hairs but refuses to "beat herself up" and instead thanks her body.

Speaking to Mailonline, she said: "Number one, I am grateful for a healthy body that has put me in good stead this far and given me two healthy children and a long career doing what I love."

Tess continued, "I try not to dwell on the negatives. I look in the mirror and see new lines every day, I'll see the odd grey hair but this is life. I tend to try and not dwell or beat myself up about what I can't change and rather focus on what I am grateful for."

Tess, who co-hosts Strictly alongside Claudia Winkleman, 48, insists she has her glam squad to thank for her immaculate look on the show each week. She often documents her outfits to her 762k followers on Instagram.

This content is imported from Instagram. You may be able to find the same content in another format, or you may be able to find more information, at their web site.

The presenter also uses her Instagram account to give an insight into family life with husband Vernon Kay and daughters Phoebe, 16 and Amber 11, including photos from their Christmas together and from their wedding vow renewal ceremony.

This content is imported from Instagram. You may be able to find the same content in another format, or you may be able to find more information, at their web site.

Last week, Tess shared how she looks after herself mentally and keeps fit during lockdown.

"Just done a quick 15 min online stretch yoga session-always helps put me in a good head space for the rest of the day; which feels all the more beneficial at the moment," she wrote on Instagram.

Strictly Come Dancing will return to the BBC later this year.

Like this article? Sign up to our newsletter to get more articles like this delivered straight to your inbox.

SIGN UP

In need of some positivity or not able to make it to the shops? Get Prima delivered directly to your door every month!

Subscribe to Prima magazine today!

SUBSCRIBE HERE

bareMinerals Ageless Genius Firming & Wrinkle Smoothing Serum 30ml

42.40

Firm things up with this wrinkle-smoothing serum that targets pesky fine lines and boosts elasticity.

Mineral gold and age-beating peptides support the skins natural collagen and help diminish the look of deep set wrinkles for more youthful-looking skin. Vitamin A aids therenewal process of ageing cells and support collagens collagen for younger-looking skin.

Olay Regenerist Anti Ageing 3 Point Super Firming Serum, 50 ml

15.74

This iconic product is one of the most popular anti-ageing serums on the market for its blend of high-performing ingredients and its affordable price tag. It smooths, revitalises, plumps, firms and improves elasticity. Not all superheroes wear capes.

The Ordinary 'Buffet' Serum 30ml

12.70

Target multiple signs of ageing at once with this excellent and ultra-affordable anti-ageing serum from no-nonsense brand The Ordinary. Just like a breakfast buffet, it contains a cocktail of hardworking ingredients to fight lines and wrinkles and pigmentation.

The INKEY List Retinol Serum 30ml

9.99

Boost cell renewal and collagen production with this brilliant age-defying serum that's also a fantastic price. Retinol kickstarts your cell turnover for a youth-boost while Squalane soothes and moisturises.

First Aid Beauty Ultra Repair Hydrating Serum (30ml)

28.00

Better than your morning smoothie, a cocktail of anti-ageing peptides and collagen work to plump skin and minimise fine lines. Hyaluronic acid also locks in moisture to hydrate thirsty skin.

Sanctuary Spa Hyaluronic Wonder Oil Serum 30ml

20.00

This raved-about 'wonder serum' is exactly that its anti-ageing and radiance-boosting properties work to create younger-looking skin.The oil phase is infused with nourishing moringa, jojoba and pomegranate oils for premium hydration, while the serum phase is enriched with red rice bio-ferment cells, which firm and lift the facial contours.

Kiehl's Powerful-Strength Line-Reducing Concentrate 50ml

52.00

Kiehl's original line-fighting serum is now boosted with hydrating hyaluronic acid for an extra youth-boost. It works to reduce the appearance of wrinkles and pores and leave skin smoother and more radiant.

Elemis Pro-Collagen Definition Face & Neck Serum, 30ml

73.60

This hardworking serum wages war onwrinkles to create a smoother skin surface.Powered by up to 1.5 million plant stem cells, which help to combat loss of density, leaving thinning skin looking more visibly toned and firmer, the serum plumps skin for a revitalised, lifted appearance.

Origins Plantscription Anti-Ageing Power Serum, 100ml

80.00

A potent youth-pop in a bottle, this seriously smart anti-ageing serum really means business, and uses a bamboo complex to fight lines and boost radiance.

Roots of Strength Firming Shaping Serum

106.67

Plump up and firm up with this all-natural, cruelty-free seruminfused with three root extracts, including ginger from Madagascar, which helps resurface your skin for a smoother complexion.

Frankincense Intense Age-Defying Serum

65.00

Invest in this serum for a complexion-clearing cocktail that includes apotent peptide complex that helps reduce the look of fine lines, gardenia stem cells help enhance skin's plumpness, while a synergistic blend of acacia Senegal helps smooth skin and banish wrinkles.

B. Nourished Advanced Serum 30ml

We're big fans of Superdrug's own B. skincare range it's really effective at purse-happy prices. This anti-ageing serum boasts high concentrations ofhyaluronic acid (hydration) niacinamide (vitamin B3 to help brighten skin), peptides (smooth wrinkles and stimulate collagen), andSpanish Needle (a retinol-like botanical that improves radiance, texture and firmness in mature skin).

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

Read the original post:
Tess Daly opens up about being "grateful" for her body and not dwelling on the negatives - Allaboutyou

Skin Stem Cells Comments Off on Tess Daly opens up about being "grateful" for her body and not dwelling on the negatives – Allaboutyou | January 19th, 2021

Global Autologous Stem Cell Based Therapies Market 2020 by Company, Type and Application, Forecast to 2025 has been updated by MarketsandResearch.biz replete with a precise analysis of the market, specifically that approach market size, trends, share, outlook, production, and futuristic development trends and present and future market status from 2020 to 2025. The report comprises of a comprehensive investigation into the geographical landscape, industry size along with the revenue estimation of the business. The report supplies a point by point analysis dependent on the exhaustive research of the global Autologous Stem Cell Based Therapies market elements like development situation, potential opportunities, and operation landscape and trend analysis. The study recognizes the factors behind the growth of certain segments and focuses on business models expected to create new revenue for market players. The report also offers insight into emerging trends and restraints.

About Manufacturers And Growing Competition:

The report highlights crucial details on specific areas comprising a detailed analytical review of the competition spectrum. Each of the leading players is thoroughly identified and profiled in the global Autologous Stem Cell Based Therapies report with their product portfolio as well as company status and portfolio. The report is a complete representation of all the major initiatives initiated by various market players across diverse geographical areas. After studying key companies, the report focuses on the new entrants contributing to the growth of the market.

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/67562

Some players from complete research coverage: Regeneus, US STEM CELL, INC., Mesoblast, Med cell Europe, Pluristem Therapeutics Inc, Tigenix, Brainstorm Cell Therapeutics

This report segments on the basis of types are: Embryonic Stem Cell, Resident Cardiac Stem Cells, Umbilical Cord Blood Stem Cells

This report segments on the basis of application are: Neurodegenerative Disorders, Autoimmune Diseases, Cardiovascular Diseases

For a comprehensive understanding of market dynamics, the global Autologous Stem Cell Based Therapies market analyzed across key geographies namely: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

The study then investigates the important achievements of the market, Research & Development, new product launch, product responses, and regional growth of the most important competitors operating in the global Autologous Stem Cell Based Therapies market. The analysis also takes into account the existing and upcoming technological aspects of the market. Finally, the report describes the sales channel, distributors, traders, dealers, research findings and Conclusion, appendix, and data source. The data about producing base distribution, sales area, product kind, market competitive scenario, and trends, market concentration rate has been given further.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/67562/global-autologous-stem-cell-based-therapies-market-2020-by-company-type-and-application-forecast-to-2025

This Comprehensive Report Will Provide:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Follow this link:
Global Autologous Stem Cell Based Therapies Market 2020 Key Drivers and Restraints, Regional Outlook, End-User Applicants by 2025 - The Pinstripe...

Cardiac Stem Cells Comments Off on Global Autologous Stem Cell Based Therapies Market 2020 Key Drivers and Restraints, Regional Outlook, End-User Applicants by 2025 – The Pinstripe… | January 14th, 2021

Retinal cell transplants are considered to be an attractive approach for treating blindness. Question is, where do you source the cells?

An international research team of scientists from Singapores Agency for Science, Technology and Research (A*STAR), the Icahn School of Medicine at Mount Sinai in New York and Germanys Eye Clinic Sulzbach is using a type of stem cell in the eye to grow the pigmented layer of retina thats essential for vision. The approach is showing promise in monkeys.

The findingssuggest that these retinal pigment epithelium (RPE) stem cell-derived RPE, or hRPESC-RPE, may be a useful source for cell replacement therapies to treatRPE-related blindness caused by diseases such as macular degeneration, the researchers suggest. The results are published in the journal Stem Cell Reports.

RPE is a layer of tissue that supports the neurosensory retina and is critical for vision. An estimated 200 million people live with diseases associated with RPE dysfunction, including macular degeneration. Early attempts at RPE replacement used cells from the patientan approach with limitationsscientists have been searching for treatment using different populations of stem cells.

In 2012, scientists identified a type of adult cell in the RPE that's normally dormant but that can be activated to take on a stem-cell-like state with self-renewing ability. These cells have the potential to differentiate into RPE cells and could therefore be used for RPE replacement therapies, the A*STAR-led team figured.

In their study, the researchers took hRPESC-RPE from donated adult eyes and grew them into RPE monolayers. When transplanted into the eyes of monkeys on a polymer scaffold, theRPE patches stably integrated for at least three months.

The stem cell-derived RPE patchespartially took over and were able to support normal light-sensing function, the team showed. Whats more, the method didnt cause vision-blocking retinal scarring that has been seen with other experimental approaches.

RELATED:Reprogrammed skin cells restore sight in mouse models of retinal disease

Multiple types of stem cells, includinghuman embryonic stem cells and human-induced pluripotent stem cells, have been proposed as alternative sources for retinal replacement. A team led by Mount Sinai previously used gene transfer to activate a type of retinal cells called Mller glial to adopt stem-cell-like characteristics. The team prompted the cells to divide into light-sensing rod photoreceptor cells in blind mice.

Researchers led by the National Institutes of Healths National Eye Institute used five chemicals to turn skin cells directly into rod photoreceptors.

The A*STAR-led researchers believetheir study demonstrates the potential of using hRPESC-RPE transplants as a treatment for macular degeneration. Further studies are needed to test the method in monkey models of eye disease to gauge the therapeutic effect, the researcher suggested.

If the cells succeed, they could serve as an unlimited resource for human RPE. Because the cells are harvested from human eyes, the researchers suggested establishing hRPESC-RPE donor banks to provide cells that match individual patients so there is noimmune rejection.

Read more:
Eye stem cell transplant to treat blindness bolsters retinal function in monkeys - FierceBiotech

Skin Stem Cells Comments Off on Eye stem cell transplant to treat blindness bolsters retinal function in monkeys – FierceBiotech | January 14th, 2021

Dr. Joshua Schiffer (third from left) and E. Fabian Cardozo-Ojeda (far right) led research published on Tuesday that provides mathematical models on strategies for optimizing treatment for HIV. (Fred Hutchinson Cancer Research Center Photo)

In the nearly four decades since HIV was discovered, only two people have been cured of the virus that has killed millions.

Researchers in Seattle are hoping to boost that number. On Tuesday, scientists from the Fred Hutchinson Cancer Research Center and the University of Washington published a study that provides clues to optimizing treatments that could wipe out HIV in infected patients.

Worldwide, some 26 million people are receiving antiviral therapy to keep the virus in check, but the drugs dont completely stamp out HIV, the virus that causes AIDS. The virus becomes latent, hiding out in cells until the drugs are gone. It gets activated again and starts reproducing.

One key component to HIVs reanimation is the presence of a molecule called CCR5 thats found on the outside of a certain class of immune system cells. The CCR5 helps the virus enter and infect new cells.

The two men seemingly cured of HIV, known as the Berlin Patient and the London Patient, also had cancer, one with acute myeloid leukemia and the other Hodgkin Lymphoma. As part of their cancer treatments, the patients received transplants of healthy stem cells, which produce immune system cells. They received the transplants from donors who lacked the gene that produces functional CCR5 molecules.

It appears that by suppressing the virus and then cutting off its pathway to resurgence, the virus can be defeated.

Since the 1960s, the Fred Hutch has been a pioneer in bone marrow transplants in cancer treatment, and researchers there are applying similar strategies for treating HIV.

Fred Hutch and UW scientists in recent years have performed experiments using pig-tailed macaques that are infected with a simian version of HIV. In one study of 22 monkeys, the infected macaques received transplants of their own stem cells, after they were treated to knock out the CCR5 gene. Researchers were interested in using the monkeys own altered cells because their immune systems would accept them and not perceive them as foreign invaders to be fought off.

One of the challenges of this approach to fighting HIV is figuring out how many of the altered stem cells are needed its difficult to produce a massive supply in order to overwhelm the cells that still produce CCR5. Add to that the rate of stem cell replication and figuring out the timing of administering and stopping antiviral drugs.

Thats where the new research comes in.

E. Fabian Cardozo-Ojeda, a senior staff scientist at the Fred Hutchs Vaccine and Infectious Disease Division, took all of the data available from the 22 monkeys to figure out how to perfect the treatment. He and his team developed a multi-stage mathematical model to calculate the effects of different amounts of residual and transplanted stem cells, the HIV viral load and the timing of when antiviral drugs are halted.

Were trying to do interdisciplinary work to get that optimal approach for a cure, Cardozo-Ojeda said.

In order to control HIV through this strategy, the researchers came to two conclusions with their formula. First, a patient needs a dose of at least five times as many transplanted stem cells compared to residual cells, and second, before a patient stops taking antiviral drugs, the cells lacking CCR5 need to total between 76-to-94% of the total transplanted stem cell population in their blood.

While the study was based on macaque data, were generating possible hypotheses of what could happen with people, Cardozo-Ojeda said. When it comes to applying their formula to higher primates, we believe that could be translated to humans for sure.

The peer-reviewed study was published by eLife, a non-profit platform. Cardozo-Ojeda is first author of the study and the other authors are Elizabeth Duke, Christopher Peterson, Daniel Reeves, Bryan Mayer, Hans-Peter Kiem and Joshua Schiffer.

Read more here:
Seattle researchers find clues for treatments that could eliminate HIV in infected patients - GeekWire

Skin Stem Cells Comments Off on Seattle researchers find clues for treatments that could eliminate HIV in infected patients – GeekWire | January 14th, 2021

By Deborah Borfitz

January 13, 2021 | As aging researchers are aware, birthday candles are not a good guide to either human health or longevity. But there is an abundance of clues in the genome and, as suggested by studies in animals, some of age-related damage is reversible by removing or reprogramming problematic cells or blocking the activity of key proteins.

As it turns out, DNA methylationa frequently-used biomarker of biological ageis not just marking time like a clock on the wall but actually controlling time within cells, according to David Sinclair, an expert on aging at Harvard Medical School and cofounder of 4-year-old Life Biosciences. The revelation emerged from a study recently published in Nature (DOI: 10.1038/s41586-020-2975-4) where Harvard researchers showed, for the first time, that the pattern of DNA methylation in the genome can be safely reset to a younger age.

It was in fact a prerequisite to restoring youthful function and vision in old mice, says Sinclair, who has spent most of his adult life studying the epigenetic changes associated with aging. Up until a few years ago, he thought the process was unidirectional and that cells ultimately lost their identity and malfunctioned or became cancerous.

It seemed crazy to try to get proteins to return to the place they were in young cells, Sinclair says. Proteins move around in response to age-associated DNA damage and end up in the wrong places on the genome, causing the wrong genes to be turned on, but scientists did not know if proteins could go back, where the instructions were stored, or if they were being stored at all.

As covered in his 2019 bestseller Lifespan, Sinclair now believes that aging is the result of the so-called epigenetic changes scrambling how the body reads genetic code. Were essentially looking for the polish to get the cell to read the genome correctly again, he says, a process he likens to recovering music on a scratched CD.

Yamanaka Factors

Sinclair and his research associates have been focusing on the eye, in part because retinal tissues start aging soon after birth, he explains. While a damaged optic nerve can heal in a newborn, the injury is irreversible in a 1-year-old.

Yuancheng Lu, a former student of Sinclairs, was also interested in the eye because his family has a vision-correction business and recognized sight loss as a huge unmet need, he continues. We thought if we could take the age of those retinal cells back far enough, but not so far that they lose their identity, we might be able to see regrowth of the optic nerve if it was damaged.

Among the foundational work was a 2016 study in Cell (DOI: 10.1016/j.cell.2016.11.052) by Life Biosciences cofounder Juan Carlos Izpisua Belmonte (Salk Institute for Biological Studies) who partially erased cellular markers of aging in mice that aged prematurely, as well as in human cells, by turning on Yamanaka factors Oct4, Sox2, Klf4, and c-Myc (OSKM) highly expressed in embryonic stem cells. Short-term induction of OSKM ameliorated hallmarks of aging and modestly extended lifespan in the short-lived mice.

The lifespan gain was widely dismissed as an artifact of shocking a mouse, says Sinclair, since the mice died if the treatment continued for more than two days. Although the human health implications appeared unlikely, his Harvard team decided to try the approach using an adeno-associated virus as a vehicle to deliver the youth-restoring OSKM genes into the retinas of aging mice.

The technology kept killing the mice or causing them to get cancer until Lu decided to drop the c-Myc genean oncogenein his experiments using human skin cells. He looked at [damaged] cells that had been expressing OSK for three weeks and the nerves were growing back toward the brain to an unprecedented degree. Moreover, the cells got older by the damage and younger by the treatment.

As the broader team went on to show in the Nature paper, the trio of Yamanaka factors effectively made cells younger without causing them to lose their identity (i.e., turning back into induced pluripotent stem cells) or fueling tumor growth even after a year of continuous treatment of the entire body of a mouse. If anything, the mice had fewer tumors over the course of the study, says Sinclair.

Although the mice needed to be autopsied to definitively measure tumor burden, Sinclair says the study will be repeated to learn if the epigenetic reprogramming technique can increase lifespan.

Findings have implications beyond the treatment of age-related diseases specific to the eye, says Sinclair. Aging researchers have published studies showing other types of tissues, including muscle and kidney cells, can also be rejuvenated.

Clocked Results

In the latest study using mice, epigenetic reprogramming was found to have three beneficial effects on the eye: promotion of optic nerve regeneration, reversal of vision loss with a condition mimicking human glaucoma, and reversal of vision loss in aging animals without glaucoma. The latter finding, from Sinclairs vantage point, is the most important one. This is ultimately a story about finding a repository of youthful information in old cells that can reverse aging.

Results of all three experiments are noteworthy and have commonly thought to be three separate processes, says Sinclair. That is only because the fields of aging and acute and chronic disease are distinct disciplines that rarely talk to each other.

The Harvard team is pioneering a new way to tackle diseases of aging by addressing the underlying cause. This is the first time, as far as Sinclair is aware, where nerve damage was studied in old rather than young animals. In the case of glaucoma and most diseases, aging is considered largely irrelevant, when of course we know glaucoma is a disease of aging.

A variety of aging clocks, including some the research team built themselves, have been deployed for studies because they are considered the most accurate predictor of biological age and future health, says Sinclair. As embryos, cells lay down different patterns of methylation to ensure they remember their purpose over the next 80 to 100 years.

For unknown reasons, methyl groups get predictably added and subtracted from DNA bases across cell and tissue types and even species, Sinclair says. In 2013, UCLAs Steve Horvath (another Life Biosciences cofounder) showed that machine learning could be used to pick out the hot spots and predict individual lifespan depending on how far above or below the DNA methylation line they sit (Genome Biology, DOI: 10.1186/gb-2013-14-10-r115).

A multitude of aging clocks have since been developed. Eventually, we will need some standardization in the field, but there is nothing super-mysterious about aging clocks, says Sinclair. One of my grad students could probably get you one by the end of the day.

Booming Field

Aging research is a rapidly accelerating field and epigenetic reprogramming is poised to become a particularly active area of inquiry. In terms of numbers, there are still only a dozen or so labs intensely working on this, but there are probably a hundred others I am aware of who are getting into it, says Sinclair.

Life Biosciences began with four labs, but new ones are now joining on an almost weekly basis, he adds. Collaborators have expanded work to the ear and other areas of the body beyond the eye, he adds.

Were also reducing the cost of the DNA clock test by orders of magnitude so [biological age prediction] can be done on millions of people, he continues. In the future, aging clocks are expected to be a routine test in physicians arsenal to guide patient care as well as to monitor response to cancer treatment.

Harvard University has already licensed two patents related to the technology used by the aging researchers to Life Biosciences, Sinclair says. The company has built a scientific team with a group of world-class advisors who developed gene therapy for the eye, which will be tested first for the treatment of glaucoma.

The role of chaperone-mediated autophagy in aging and age-related diseases is another promising area of research being pursued by Life Biosciences Ana Maria Cuervo, M.D, Ph.D., professor, and co-director of the Institute of Aging Studies at the Albert Einstein College of Medicine. Cuervo recently reported at a meeting that fasting-induced autophagy, the cells natural mechanism for removes unnecessary or dysfunctional components, can greatly extend the lifespan of mice. She believes the triggering of this process might one day help treat diseases such as macular degeneration and Alzheimers.

The specialty of Manuel Serrano, Ph.D., the fourth company cofounder, is cellular senescence and reprogramming and how they relate to degenerative diseases of the lung, kidney, and heart. He isan internationally recognized scientist who has made significant contributions to cancer and aging research and works in the Institute for Research Biomedicine in Barcelona.

The rest is here:
Reversing The Aging Clock With Epigenetic Reprogramming - Bio-IT World

Skin Stem Cells Comments Off on Reversing The Aging Clock With Epigenetic Reprogramming – Bio-IT World | January 14th, 2021

This article was originally published here

Stem Cell Res Ther. 2021 Jan 13;12(1):58. doi: 10.1186/s13287-020-02110-x.

ABSTRACT

INTRODUCTION: Critical limb ischemia (CLI) is the most advanced form of peripheral arterial disease (PAD) characterized by ischemic rest pain and non-healing ulcers. Currently, the standard therapy for CLI is the surgical reconstruction and endovascular therapy or limb amputation for patients with no treatment options. Neovasculogenesis induced by mesenchymal stem cells (MSCs) therapy is a promising approach to improve CLI. Owing to their angiogenic and immunomodulatory potential, MSCs are perfect candidates for the treatment of CLI. The purpose of this study was to determine and compare the in vitro and in vivo effects of allogeneic bone marrow mesenchymal stem cells (BM-MSCs) and adipose tissue mesenchymal stem cells (AT-MSCs) on CLI treatment.

METHODS: For the first step, BM-MSCs and AT-MSCs were isolated and characterized for the characteristic MSC phenotypes. Then, femoral artery ligation and total excision of the femoral artery were performed on C57BL/6 mice to create a CLI model. The cells were evaluated for their in vitro and in vivo biological characteristics for CLI cell therapy. In order to determine these characteristics, the following tests were performed: morphology, flow cytometry, differentiation to osteocyte and adipocyte, wound healing assay, and behavioral tests including Tarlov, Ischemia, Modified ischemia, Function and the grade of limb necrosis scores, donor cell survival assay, and histological analysis.

RESULTS: Our cellular and functional tests indicated that during 28 days after cell transplantation, BM-MSCs had a great effect on endothelial cell migration, muscle restructure, functional improvements, and neovascularization in ischemic tissues compared with AT-MSCs and control groups.

CONCLUSIONS: Allogeneic BM-MSC transplantation resulted in a more effective recovery from critical limb ischemia compared to AT-MSCs transplantation. In fact, BM-MSC transplantation could be considered as a promising therapy for diseases with insufficient angiogenesis including hindlimb ischemia.

PMID:33436054 | DOI:10.1186/s13287-020-02110-x

Read more here:
Comparative analysis of mouse bone marrow and adipose tissue mesenchymal stem cells for critical limb ischemia cell therapy - DocWire News

Bone Marrow Stem Cells Comments Off on Comparative analysis of mouse bone marrow and adipose tissue mesenchymal stem cells for critical limb ischemia cell therapy – DocWire News | January 14th, 2021

A SHIPYARD worker has potentially saved a stranger's life after donating his stem cells to a person in desperate need.

Brad Lawson, from Walney, first signed up to be a stem cell donor six years ago after an event at his college.

Stem cells are cells with the potential to develop into many different types of cells in the body.

Every 14 minutes, someone is diagnosed with blood cancer such as leukaemia.

For many, a bone marrow or blood stem cell transplant is their only chance.

They need cells from a healthy person with the same tissue type to replace and repair their own damaged cells.

About 30 per cent of people in need can find a suitable donor in their family but the other 70 per cent rely on a stranger to save their lives.

This is what prompted Mr Lawson to travel hundreds of miles to London to give his much-needed donation.

The 23-year-old said: "I first signed onto the register six years ago and hadn't thought much about it since.

"Then I was shocked to get a phone call the other week to say they'd matched a patient with my stem cells.

"It's quite rare to match with someone - it's only one in 800 people so I knew I had to help."

Mr Lawson travelled down to London where he underwent peripheral blood stem cell collection.

The process involves having a course of injections prior to collection to stimulate the bone marrow and increase the number of stem cells and white blood cells in the blood.

He said: "I had no hesitation about going down there when I got the call. When you sign up, you need to be fully committed if you do get a call.

"This could be someone's chance of survival and I would never pull out of something like that.

"The process was actually really easy. It takes about five hours and isn't painful at all.

"I absolutely hate needles and didn't find it painful at all."

Mr Lawson said it felt 'rewarding' to know his donation could have possibly saved a stranger's life.

"You could potentially give someone the chance to survive by signing up," he said.

"It's an amazing thing to do which could seriously make a difference.

"I may be in that position one day where I desperately need stem cells and would like to think someone out there would help me.

"Donations literally saves lives. It's a really rewarding thing to do to be able to help someone in this way."

Mr Lawson is urging the public to sign up to the register.

"Only about two per cent of people in the UK are actually on the register," he said.

"I'm telling everyone to sign up and raise awareness of stem cell donation.

"The more people we can get to sign up, and save lives, the better."

To register, visit: http://www.dkms.org.uk/en/register-now.

Here is the original post:
Shipyard worker Brad Lawson from Walney may have saved a stranger's life with his stem cell donation - NW Evening Mail

Bone Marrow Stem Cells Comments Off on Shipyard worker Brad Lawson from Walney may have saved a stranger’s life with his stem cell donation – NW Evening Mail | January 14th, 2021

Full TitleCord Blood Transplantation in Children and Young Adults with Hematologic Malignancies and Non-Malignant DisordersPurpose

The transplantation of stem cells from umbilical cord blood is a treatment for some blood cancers and non-cancerous blood or metabolic disorders. Patients routinely receive high doses of chemotherapy and sometimes radiation before receiving the stem cells to help make room in the bone marrow for new blood stem cells to grow, prevent the body from rejecting the transplanted cells, and help kill any abnormal blood cells in the body. However, the combination of these treatments can have serious side effects.

Researchers are doing this study to find out whether a combination of the chemotherapy drugs clofarabine, fludarabine, and busulfan (without radiation) is a safe and effective treatment for children and young adults receiving cord blood transplants for blood cancers or non-cancerous blood or metabolic disorders. These three drugs are given intravenously (by vein).

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

For more information about this study and to inquire about eligibility, please contact 1-833-MSK-KIDS.

See the original post:
A Study of Cord Blood Transplantation in Children and Young Adults with Blood Cancers and Non-Cancerous Blood Disorders - On Cancer - Memorial Sloan...

Bone Marrow Stem Cells Comments Off on A Study of Cord Blood Transplantation in Children and Young Adults with Blood Cancers and Non-Cancerous Blood Disorders – On Cancer – Memorial Sloan… | January 14th, 2021

The Adipose Derived Stem Cell Therapy Market Research Report is a resource, which provides current as well as upcoming technical and financial details of the industry to 2027. This report gives you so important and essentials data of Market size, share, trends, Growth, applications, forecast and cost analysis. Delivery development in North America, China, Europe, and South East Asia, Japan as well as in the Globe. The report proves to be indispensable when it comes to market definition, classifications, applications and engagements. The market report also computes the market size and revenue generated from the sales. The industry analysis report presents the key statistics on the market status of global and regional manufacturers and also acts as a valuable source of leadership and direction. What is more, theAdipose Derived Stem Cell Therapy market report analyses and provides historic data along with the current performance of the market

Adipose derived stem cells (ADSCs) are stem cells derived from adipocytes, and can differentiate into variety of cell types. ADSCs have multipotency similar to bone marrow mesenchymal stem cells, thus ADSCs substitute for bone marrow as a source of stem cells. Numerous manual and automatic stem cell separation procedures are adopted in order to separate adipose stem cells (ASCs) from adipose tissue. Flow cytometry can also be used to isolate ADSCs from other stem cells within a cell solution.

This Press Release will help you to Know the Volume, growth with Impacting Trends. Get SAMPLE PDF (Including Full TOC, Table & Figures) at:

Get PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2357

Global Adipose Derived Stem Cell Therapy Market competition by Top Key Players: BioRestorative Therapies, Inc., Celltex Therapeutics Corporation, Antria, Inc., Cytori Therapeutics Inc., Intrexon Corporation, Mesoblast Ltd., iXCells Biotechnologies, Pluristem Therapeutics, Inc., Thermo Fisher Scientific, Inc., Tissue Genesis, Inc., Cyagen US Inc., Celprogen, Inc., and Lonza Group, among others.

Adipose Derived Stem Cell Therapy Market section by Region:

The Middle East and Africa North AmericaSouth AmericaEuropeAsia-Pacific

Segmentation: The report has been separated into different categories, such as product type, application, end user, and region. Every segment is evaluated based on the CAGR, share and growth potential. In the regional analysis, the report highlights the prospective region, which should generate opportunities in the global Adipose Derived Stem Cell Therapy market in the years to come. This segmented analysis will surely prove to be a useful tool for readers, stakeholders and market participants to get a full picture of the Adipose Derived Stem Cell Therapy global market and its growth potential in the years to come.

TheAdipose Derived Stem Cell TherapyMarket report offers a plethora of insights which include:

LIMITED TIME OFFER Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report

Apply Promo Code CMIFIRST1000 And Get Instant Discount Of USD 1000

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/2357

Important Information that can be extracted from the Report:

Assessment of the COVID-19 impact on the growth of the Adipose Derived Stem Cell Therapy MarketSuccessful market entry strategies formulated by emerging market playersPricing and marketing strategies adopted by established market playersCountry-wise assessment of the Adipose Derived Stem Cell Therapy Market in key regionsYear-on-Year growth of each market segment over the forecast period 2026

TheAdipose Derived Stem Cell TherapyMarket report considers the following years to predict market growth:

The GlobalAdipose Derived Stem Cell TherapyMarket is displayed in 13 Chapters:

Chapter 1: Market Overview, Drivers, Restraints and OpportunitiesChapter 2: Market Competition by ManufacturersChapter 3: Production by RegionsChapter 4: Consumption by RegionsChapter 5: Production, By Types, Revenue and Market share by TypesChapter 6: Consumption, By Applications, Market share (%) and Growth Rate by ApplicationsChapter 7: Complete profiling and analysis of ManufacturersChapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expensesChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Market ForecastChapter 13:Adipose Derived Stem Cell Therapy Research Findings and Conclusion, Appendix, methodology and data source

More here:
Adipose Derived Stem Cell Therapy Market Analysis and Forecast, 2020-2026 Coherent Market Insights | BioRestorative Therapies, Inc., Celltex...

Bone Marrow Stem Cells Comments Off on Adipose Derived Stem Cell Therapy Market Analysis and Forecast, 2020-2026 Coherent Market Insights | BioRestorative Therapies, Inc., Celltex… | January 14th, 2021

This article was originally published here

Cancers (Basel). 2021 Jan 10;13(2):E226. doi: 10.3390/cancers13020226.

ABSTRACT

Accumulating evidence demonstrates important roles for natural killer (NK) cells in controlling multiple myeloma (MM). A prospective flow cytometry-based analysis of NK cells in the blood and bone marrow (BM) of MM patient subgroups was performed (smoldering (SMM), newly diagnosed (ND), relapsed/refractory, (RR) and post-stem cell transplantation (pSCT)). Assessments included the biomarker expression and function of NK cells, correlations between the expression of receptors on NK cells with their ligands on myeloma cells, and comparisons between MM patient subgroups and healthy controls. The most striking differences from healthy controls were found in RR and pSCT patients, in which NK cells were less mature and expressed reduced levels of the activating receptors DNAM-1, NKG2D, and CD16. These differences were more pronounced in the BM than in blood, including upregulation of the therapeutic targets TIM3, TIGIT, ICOS, and GITR. Their expression suggests NK cells became exhausted upon chronic encounters with the tumor. A high expression of SLAMF7 on blood NK cells correlated with shorter progression-free survival. This correlation was particularly evident in ND patients, including on mature CD56dim NK cells in the BM. Thus, our NK cell analysis identified possible therapeutic targets in MM and a biomarker with prognostic potential for disease progression.

PMID:33435153 | DOI:10.3390/cancers13020226

Read more here:
Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma - DocWire News

Bone Marrow Stem Cells Comments Off on Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma – DocWire News | January 14th, 2021